C50.829 — Malignant neoplasm of overlapping sites of unspecified male breast
Is C50.829 billable?
Yes, but C50.829 is an unspecified code. C50.829 is a valid, billable ICD-10-CM code for encounters from October 1, 2026 through September 30, 2027. However, C50.829 is an unspecified or catch-all code. Payers apply additional scrutiny to unspecified codes and many deny them when the medical record supports a more specific option, so check the documentation before selecting C50.829 — the more specific alternatives are listed below.
C50.829 at a glance
| Code | C50.829 |
|---|---|
| Description | Malignant neoplasm of overlapping sites of unspecified male breast |
| Billable | Yes |
| Code set | ICD-10-CM FY2027 |
| Valid for encounters | October 1, 2026 – September 30, 2027 |
Which MS-DRGs does C50.829 group to?
C50.829 sits in MDC 09 and helps define the logic of 2 MS-DRGs (version 44, FY2027). Which one a stay actually groups to also depends on procedures and secondary diagnoses.
- 582Mastectomy for Malignancy with CC/MCCsurgical
- 583Mastectomy for Malignancy without CC/MCCsurgical
Excludes1 — never code together — inherited from C50
The conditions below can never be reported together with C50.829 on the same claim. An Excludes1 note means the two conditions cannot occur in the same patient, so reporting both is a coding error.
Use additional code — inherited from C50
Report an additional code alongside C50.829 to fully describe the condition. C50.829 is sequenced first.
- code to identify estrogen, and other hormones and factors receptor status (Z17.-)
How long has C50.829 existed?
C50.829 has been in ICD-10-CM since at least FY2016, the earliest fiscal year on record here.
Derived from the official order files for FY2016–FY2026. FY2017 and FY2020 publish no order file, so those years are not covered.